Thomas Thum

List of Publications by Year
in descending order

451 papers	38,410 citations	2538 96 h-index	3638 180 g-index
467 all docs	467 docs citations	467 times ranked	47074 citing authors

#	Article	IF	Citations
1	Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy, 2016, 12, 1-222.	4.3	4,701
2	MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature, 2008, 456, 980-984.	13.7	2,111
3	Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. Physiological Reviews, 2016, 96, 1297-1325.	13.1	1,426
4	MicroRNAs in the Human Heart. Circulation, 2007, 116, 258-267.	1.6	852
5	Cardiac fibroblastâ€“derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy. Journal of Clinical Investigation, 2014, 124, 2136-2146.	3.9	803
6	Circulating Long Noncoding RNA, LIPCAR, Predicts Survival in Patients With Heart Failure. Circulation Research, 2014, 114, 1569-1575.	2.0	542
7	The miRNA-212/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy. Nature Communications, 2012, 3, 1078.	5.8	518
8	Regulation and function of miRNA-21 in health and disease. RNA Biology, 2011, 8, 706-713.	1.5	499
9	Effect of Intravenous Iron Sucrose on Exercise Tolerance in Anemic and Nonanemic Patients With Symptomatic Chronic Heart Failure and Iron Deficiency. Journal of the American College of Cardiology, 2008, 51, 103-112.	1.2	488
10	LDL Cholesterol Upregulates Synthesis of Asymmetrical Dimethylarginine in Human Endothelial Cells. Circulation Research, 2000, 87, 99-105.	2.0	461
11	Exosomes: New players in cellâ€“cell communication. International Journal of Biochemistry and Cell Biology, 2012, 44, 2060-2064.	1.2	399
12	Endothelial Nitric Oxide Synthase Uncoupling Impairs Endothelial Progenitor Cell Mobilization and Function in Diabetes. Diabetes, 2007, 56, 666-674.	0.3	371
13	Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>tudy <scp>G</scp>roup of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology in collaboration with the <scp>I</scp>nternational <scp>C</scp>ardioâ€<scp>O</scp>ncology <scp>S</scp>ociety. European Journal of Heart Failure, 2020,	2.9	364
14	MicroRNA-24 Regulates Vascularity After Myocardial Infarction. Circulation, 2011, 124, 720-730.	1.6	358
15	Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome. Journal of Molecular and Cellular Cardiology, 2011, 51, 872-875.	0.9	350
16	Long Noncoding RNAs and MicroRNAs in Cardiovascular Pathophysiology. Circulation Research, 2015, 116, 751-762.	2.0	334
17	Long noncoding RNA <i>Chast</i> promotes cardiac remodeling. Science Translational Medicine, 2016, 8, 326ra22.	5.8	321
18	Circulating Noncoding RNAs as Biomarkers of Cardiovascular Disease and Injury. Circulation Research, 2017, 120, 381-399.	2.0	319

#	Article	IF	Citations
19	MicroRNAs: novel regulators in cardiac development and disease. Cardiovascular Research, 2008, 79, 562-570.	1.8	310
20	Non-coding RNAs in cardiovascular diseases: diagnostic and therapeutic perspectives. European Heart Journal, 2018, 39, 2704-2716.	1.0	300
21	Long noncoding RNAs in cardiac development and ageing. Nature Reviews Cardiology, 2015, 12, 415-425.	6.1	296
22	Inhibition of the Cardiac Fibroblastâ€"Enriched lncRNA <i>Meg3</i> Prevents Cardiac Fibrosis and Diastolic Dysfunction. Circulation Research, 2017, 121, 575-583.	2.0	281
23	Myocardial fibrosis: biomedical research from bench to bedside. European Journal of Heart Failure, 2017, 19, 177-191.	2.9	280
24	Long noncoding RNAs in kidney and cardiovascular diseases. Nature Reviews Nephrology, 2016, 12, 360-373.	4.1	273
25	Age-Dependent Impairment of Endothelial Progenitor Cells Is Corrected by Growth Hormone Mediated Increase of Insulin-Like Growth Factor-1. Circulation Research, 2007, 100, 434-443.	2.0	269
26	Circulating MicroRNAs as Biomarkers and Potential Paracrine Mediators of Cardiovascular Disease. Circulation: Cardiovascular Genetics, 2010, 3, 484-488.	5.1	262
27	Transforming Growth Factor-Î²â€"Induced Endothelial-to-Mesenchymal Transition Is Partly Mediated by MicroRNA-21. Arteriosclerosis, Thrombosis, and Vascular Biology, 2012, 32, 361-369.	1.1	259
28	Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation (<scp>HFA</scp>), the <scp>E</scp>uropean <scp>A</scp>ssociation of <scp>C</scp>ardiovascular <scp>I</scp>maging (<scp>EACVI</scp>) and the <scp>Cardioâ€Oncology C</scp>ouncil of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 1504-1524.	2.9	234
29	Role of miR-21 in the pathogenesis of atrial fibrosis. Basic Research in Cardiology, 2012, 107, 278.	2.5	227
30	Non-coding RNAs in Cardiac Remodeling and Heart Failure. Circulation Research, 2013, 113, 676-689.	2.0	225
31	Macrophage MicroRNA-155 Promotes Cardiac Hypertrophy and Failure. Circulation, 2013, 128, 1420-1432.	1.6	225
32	Suppression of Endothelial Progenitor Cells in Human Coronary Artery Disease by the Endogenous Nitric Oxide Synthase Inhibitor Asymmetric Dimethylarginine. Journal of the American College of Cardiology, 2005, 46, 1693-1701.	1.2	221
33	A signature of circulating microRNAs differentiates takotsubo cardiomyopathy from acute myocardial infarction. European Heart Journal, 2014, 35, 999-1006.	1.0	219
34	RNA-based diagnostic and therapeutic strategies for cardiovascular disease. Nature Reviews Cardiology, 2019, 16, 661-674.	6.1	218
35	Circulating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertension. Circulation, 2008, 117, 3020-3030.	1.6	208
36	MicroRNA-21: From Cancer to Cardiovascular Disease. Current Drug Targets, 2010, 11, 926-935.	1.0	204

#	Article	IF	Citations
37	Effects of Physical Exercise on Myocardial Telomere-Regulating Proteins, Survival Pathways, and Apoptosis. Journal of the American College of Cardiology, 2008, 52, 470-482.	1.2	203
38	MiR-378 Controls Cardiac Hypertrophy by Combined Repression of Mitogen-Activated Protein Kinase Pathway Factors. Circulation, 2013, 127, 2097-2106.	1.6	203
39	Long Noncoding RNAs in Cardiovascular Pathology, Diagnosis, and Therapy. Circulation, 2016, 134, 1484-1499.	1.6	202
40	Circulating micrornas as potential biomarkers of aerobic exercise capacity. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 306, H557-H563.	1.5	195
41	The continuous heart failure spectrum: moving beyond an ejection fraction classification. European Heart Journal, 2019, 40, 2155-2163.	1.0	195
42	MicroRNAs as mediators and therapeutic targets in chronic kidney disease. Nature Reviews Nephrology, 2011, 7, 286-294.	4.1	191
43	Novel antisense therapy targeting microRNA-132 in patients with heart failure: results of a first-in-human Phase 1b randomized, double-blind, placebo-controlled study. European Heart Journal, 2021, 42, 178-188.	1.0	190
44	The Dying Stem Cell Hypothesis. Journal of the American College of Cardiology, 2005, 46, 1799-1802.	1.2	184
45	MicroRNA signatures differentiate preserved from reduced ejection fraction heart failure. European Journal of Heart Failure, 2015, 17, 405-415.	2.9	182
46	Towards better definition, quantification and treatment of fibrosis in heart failure. A scientific roadmap by the Committee of Translational Research of the Heart Failure Association (HFA) of the European Society of Cardiology. European Journal of Heart Failure, 2019, 21, 272-285.	2.9	182
47	Urinary miR-210 as a Mediator of Acute T-Cell Mediated Rejection in Renal Allograft Recipients. American Journal of Transplantation, 2011, 11, 2221-2227.	2.6	181
48	Circulating miR-210 Predicts Survival in Critically Ill Patients with Acute Kidney Injury. Clinical Journal of the American Society of Nephrology: CJASN, 2011, 6, 1540-1546.	2.2	181
49	Circular RNAs: A Novel Class of Functional RNA Molecules with a Therapeutic Perspective. Molecular Therapy, 2019, 27, 1350-1363.	3.7	179
50	Short Communication: Asymmetric Dimethylarginine Impairs Angiogenic Progenitor Cell Function in Patients With Coronary Artery Disease Through a MicroRNA-21â€"Dependent Mechanism. Circulation Research, 2010, 107, 138-143.	2.0	177
51	Gene expression in distinct regions of the heart. Lancet, The, 2000, 355, 979-983.	6.3	174
52	Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression. Circulation Research, 2018, 122, 246-254.	2.0	174
53	MicroRNA therapeutics in cardiovascular medicine. EMBO Molecular Medicine, 2012, 4, 3-14.	3.3	173
54	Cardiac myocyte miR-29 promotes pathological remodeling of the heart by activating Wnt signaling. Nature Communications, 2017, 8, 1614.	5.8	172

#	Article	IF	Citations
55	Circular <scp>RNAs</scp> in heart failure. European Journal of Heart Failure, 2017, 19, 701-709.	2.9	168
56	Prevention of liver cancer cachexia-induced cardiac wasting and heart failure. European Heart Journal, 2014, 35, 932-941.	1.0	167
57	Noncoding RNAs and myocardial fibrosis. Nature Reviews Cardiology, 2014, 11, 655-663.	6.1	165
58	Patient profiling in heart failure for tailoring medical therapy. A consensus document of the <scp>Heart Failure Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2021, 23, 872-881.	2.9	160
59	Resveratrol Reverses Endothelial Nitric-Oxide Synthase Uncoupling in Apolipoprotein E Knockout Mice. Journal of Pharmacology and Experimental Therapeutics, 2010, 335, 149-154.	1.3	154
60	MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age, 2013, 35, 747-762.	3.0	150
61	Therapeutic miR-21 Silencing Ameliorates Diabetic Kidney Disease in Mice. Molecular Therapy, 2017, 25, 165-180.	3.7	149
62	Hallmarks of ion channel gene expression in endâ€stage heart failure. FASEB Journal, 2003, 17, 1592-1608.	0.2	146
63	Biogenesis and Regulation of Cardiovascular MicroRNAs. Circulation Research, 2011, 109, 334-347.	2.0	146
64	Regulated microRNAs in the CSF of patients with multiple sclerosis. Neurology, 2012, 79, 2166-2170.	1.5	146
65	miR-212 and miR-132 are required for epithelial stromal interactions necessary for mouse mammary gland development. Nature Genetics, 2010, 42, 1101-1108.	9.4	140
66	Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease. Circulation Research, 2020, 126, 663-678.	2.0	140
67	Endogenous Nitric Oxide Synthesis Inhibitor Asymmetric Dimethyl l -Arginine Accelerates Endothelial Cell Senescence. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1816-1822.	1.1	134
68	European Society of Cardiology/Heart Failure Association position paper on the role and safety of new glucoseâ€lowering drugs in patients with heart failure. European Journal of Heart Failure, 2020, 22, 196-213.	2.9	131
69	SERCA2a gene therapy restores microRNA-1 expression in heart failure via an Akt/FoxO3A-dependent pathway. European Heart Journal, 2012, 33, 1067-1075.	1.0	130
70	MicroRNA-24 Antagonism Prevents Renal Ischemia Reperfusion Injury. Journal of the American Society of Nephrology: JASN, 2014, 25, 2717-2729.	3.0	128
71	Circulating long-non coding RNAs as biomarkers of left ventricular diastolic function and remodelling in patients with well-controlled type 2 diabetes. Scientific Reports, 2016, 6, 37354.	1.6	128
72	Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure. Nature Cell Biology, 2013, 15, 1282-1293.	4.6	126

#	Article	IF	Citations
73	MicroRNAs in Hypertension: Mechanisms and Therapeutic Targets. Current Hypertension Reports, 2012, 14, 79-87.	1.5	125
74	Diabetes-Associated MicroRNAs in Pediatric Patients With Type 1 Diabetes Mellitus: A Cross-Sectional Cohort Study. Journal of Clinical Endocrinology and Metabolism, 2014, 99, E1661-E1665.	1.8	125
75	Impairment of Wound Healing in Patients With Type 2 Diabetes Mellitus Influences Circulating MicroRNA Patterns via Inflammatory Cytokines. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1480-1488.	1.1	123
76	Preclinical development of a miR-132 inhibitor for heart failure treatment. Nature Communications, 2020, 11, 633.	5.8	123
77	Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB Journal, 2002, 16, 1537-1549.	0.2	121
78	Signal transducer and activator of transcription 3-mediated regulation of miR-199a-5p links cardiomyocyte and endothelial cell function in the heart: a key role for ubiquitin-conjugating enzymes. European Heart Journal, 2011, 32, 1287-1297.	1.0	119
79	Mechanisms underlying recoupling of eNOS by HMG-CoA reductase inhibition in a rat model of streptozotocin-induced diabetes mellitus. Atherosclerosis, 2008, 198, 65-76.	0.4	118
80	MicroRNAs in Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 201-205.	1.1	118
81	The innate immune system in chronic cardiomyopathy: a European Society of Cardiology (ESC) scientific statement from the Working Group on Myocardial Function of the ESC. European Journal of Heart Failure, 2018, 20, 445-459.	2.9	118
82	Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. European Heart Journal, 2015, 36, 2184-2196.	1.0	117
83	Therapeutic and Diagnostic Translation of Extracellular Vesicles in Cardiovascular Diseases. Circulation, 2021, 143, 1426-1449.	1.6	116
84	Epigenetic modifications in cardiovascular disease. Basic Research in Cardiology, 2012, 107, 245.	2.5	114
85	Epigenomic and transcriptomic approaches in the post-genomic era: path to novel targets for diagnosis and therapy of the ischaemic heart? Position Paper of the European Society of Cardiology Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2017, 113, 725-736.	1.8	114
86	Improvement in Left Ventricular Remodeling by the Endothelial Nitric Oxide Synthase Enhancer AVE9488 After Experimental Myocardial Infarction. Circulation, 2008, 118, 818-827.	1.6	111
87	SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: From basic science to clinical implications. Journal of Molecular and Cellular Cardiology, 2020, 144, 47-53.	0.9	111
88	Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. European Journal of Heart Failure, 2015, 17, 764-771.	2.9	109
89	Senescence-induced inflammation: an important player and key therapeutic target in atherosclerosis. European Heart Journal, 2020, 41, 2983-2996.	1.0	108
90	Expression of Xenobiotic Metabolizing Enzymes in Different Lung Compartments of Smokers and Nonsmokers. Environmental Health Perspectives, 2006, 114, 1655-1661.	2.8	107

#	Article	IF	Citations
91	Circulating cardiovascular <scp>microRNAs</scp> inÂcritically ill <scp>COVID</scp>â€19 patients. European Journal of Heart Failure, 2021, 23, 468-475.	2.9	107
92	MicroRNAs associated with ischemia-reperfusion injury and cardioprotection by ischemic pre- and postconditioning: protectomiRs. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H216-H227.	1.5	106
93	Heart Failure Association of the ESC, Heart Failure Society of America and Japanese Heart Failure Society Position statement on endomyocardial biopsy. European Journal of Heart Failure, 2021, 23, 854-871.	2.9	105
94	A phenotypic screen to identify hypertrophy-modulating microRNAs in primary cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2012, 52, 13-20.	0.9	104
95	Development of Long Noncoding RNA-Based Strategies to Modulate TissueÂVascularization. Journal of the American College of Cardiology, 2015, 66, 2005-2015.	1.2	103
96	Circulating Long Noncoding RNA TapSAKI Is a Predictor of Mortality in Critically Ill Patients with Acute Kidney Injury. Clinical Chemistry, 2015, 61, 191-201.	1.5	103
97	Long Non-coding RNAs: At the Heart of Cardiac Dysfunction?. Frontiers in Physiology, 2019, 10, 30.	1.3	103
98	Comparison of different miR-21 inhibitor chemistries in a cardiac disease model. Journal of Clinical Investigation, 2011, 121, 461-462.	3.9	101
99	Attenuated palmitoylation of serotonin receptor 5-HT1A affects receptor function and contributes to depression-like behaviors. Nature Communications, 2019, 10, 3924.	5.8	100
100	Sodiumâ€“glucose coâ€transporter 2 inhibitors in heart failure: beyond glycaemic control. A position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1495-1503.	2.9	100
101	Preclinical Development of a MicroRNA-Based Therapy for Elderly Patients With Myocardial Infarction. Journal of the American College of Cardiology, 2016, 68, 1557-1571.	1.2	99
102	Bone marrow molecular alterations after myocardial infarction: Impact on endothelial progenitor cells. Cardiovascular Research, 2006, 70, 50-60.	1.8	98
103	Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. International Journal of Cardiology, 2013, 168, 1837-1840.	0.8	94
104	Common mechanistic pathways in cancer and heart failure. A scientific roadmap on behalf of the <scp>Translational Research Committee</scp> of the <scp>Heart Failure Association</scp> (<scp>HFA</scp>) of the <scp>European Society of Cardiology</scp> (<scp>ESC</scp>). European Journal of Heart Failure, 2020, 22, 2272-2289.	2.9	92
105	miRNA screening reveals a new miRNA family stimulating iPS cell generation via regulation of Meox2. EMBO Reports, 2011, 12, 1153-1159.	2.0	91
106	Complex roads from genotype to phenotype in dilated cardiomyopathy: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1287-1303.	1.8	91
107	Targeting myocardial remodelling to develop novel therapies for heart failure. European Journal of Heart Failure, 2014, 16, 494-508.	2.9	90
108	microRNA Therapeutics in Cardiovascular Disease Models. Annual Review of Pharmacology and Toxicology, 2014, 54, 185-203.	4.2	89

#	Article	IF	Citations
109	MicroRNAs in Serum and Bile of Patients with Primary Sclerosing Cholangitis and/or Cholangiocarcinoma. PLoS ONE, 2015, 10, e0139305.	1.1	88
110	Hypoxia-Induced MicroRNA-212/132 Alter Blood-Brain Barrier Integrity Through Inhibition of Tight Junction-Associated Proteins in Human and Mouse Brain Microvascular Endothelial Cells. Translational Stroke Research, 2019, 10, 672-683.	2.3	86
111	Plasma circular RNA hsa_circ_0001445 and coronary artery disease: Performance as a biomarker. FASEB Journal, 2020, 34, 4403-4414.	0.2	86
112	MicroRNAs targeting the SARS-CoV-2 entry receptor ACE2 in cardiomyocytes. Journal of Molecular and Cellular Cardiology, 2020, 148, 46-49.	0.9	85
113	MicroRNAs play a role in spontaneous recovery from acute liver failure. Hepatology, 2014, 60, 1346-1355.	3.6	84
114	Circulating and Urinary microRNAs in Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 1528-1533.	2.2	83
115	Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. International Journal of Cardiology, 2015, 196, 115-122.	0.8	83
116	Long Noncoding RNA-Enriched Vesicles Secreted by Hypoxic Cardiomyocytes Drive Cardiac Fibrosis. Molecular Therapy - Nucleic Acids, 2019, 18, 363-374.	2.3	83
117	SLC26A9-mediated chloride secretion prevents mucus obstruction in airway inflammation. Journal of Clinical Investigation, 2012, 122, 3629-3634.	3.9	83
118	Molecular Diagnosis of a Familial Nonhemolytic Hyperbilirubinemia (Gilbert's Syndrome) in Healthy Subjects. Hepatology, 2000, 32, 792-795.	3.6	82
119	Cardiovascular Importance of the MicroRNAâ€23/27/24 Family. Microcirculation, 2012, 19, 208-214.	1.0	82
120	AntimiR-21 Prevents Myocardial Dysfunction in a Pig Model of Ischemia/Reperfusion Injury. Journal of the American College of Cardiology, 2020, 75, 1788-1800.	1.2	82
121	An integrative translational approach to study heart failure with preserved ejection fraction: a position paper from the Working Group on Myocardial Function of the European Society of Cardiology. European Journal of Heart Failure, 2018, 20, 216-227.	2.9	81
122	Targeting muscle-enriched long non-coding RNA <i>H19</i> reverses pathological cardiac hypertrophy. European Heart Journal, 2020, 41, 3462-3474.	1.0	81
123	Glucocorticoid Insensitivity at the Hypoxic Bloodâ€“Brain Barrier Can Be Reversed by Inhibition of the Proteasome. Stroke, 2011, 42, 1081-1089.	1.0	79
124	Critical Role of the Nitric Oxide/Reactive Oxygen Species Balance in Endothelial Progenitor Dysfunction. Antioxidants and Redox Signaling, 2011, 15, 933-948.	2.5	77
125	Accurate quantification of dimethylamine (DMA) in human urine by gas chromatographyâ€“mass spectrometry as pentafluorobenzamide derivative: Evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 851, 229-239.	1.2	74
126	Vascular importance of the miR-212/132 cluster. European Heart Journal, 2014, 35, 3224-3231.	1.0	74

#	Article	IF	Citations
127	Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine?. European Heart Journal, 2019, 40, 1643-1650.	1.0	72
128	Towards standardization of echocardiography for the evaluation of left ventricular function in adult rodents: a position paper of the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 43-59.	1.8	72
129	Cardiac myocyteâ€“secreted cAMP exerts paracrine action via adenosine receptor activation. Journal of Clinical Investigation, 2014, 124, 5385-5397.	3.9	70
130	CDR132L improves systolic and diastolic function in a large animal model of chronic heart failure. European Heart Journal, 2021, 42, 192-201.	1.0	70
131	Hypoxia-induced long non-coding RNA Malat1 is dispensable for renal ischemia/reperfusion-injury. Scientific Reports, 2018, 8, 3438.	1.6	69
132	Endogenous Tumor Suppressor microRNA-193b: Therapeutic and Prognostic Value in Acute Myeloid Leukemia. Journal of Clinical Oncology, 2018, 36, 1007-1016.	0.8	67
133	<scp>Heart Failure Association</scp> of the <scp>European Society of Cardiology</scp> update on sodiumâ€“glucose coâ€•transporter 2 inhibitors in heart failure. European Journal of Heart Failure, 2020, 22, 1984-1986.	2.9	66
134	Differential Effects of Organic Nitrates on Endothelial Progenitor Cells Are Determined by Oxidative Stress. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 748-754.	1.1	65
135	Tissue-Specific Effects of the Nuclear Factor ÎºB Subunit p50 on Myocardial Ischemia-Reperfusion Injury. American Journal of Pathology, 2007, 171, 507-512.	1.9	65
136	Circulating microRNAs and Outcome in Patients with Acute Heart Failure. PLoS ONE, 2015, 10, e0142237.	1.1	65
137	Long Noncoding RNAs in Urine Are Detectable and May Enable Early Detection of Acute T Cellâ€“Mediated Rejection of Renal Allografts. Clinical Chemistry, 2015, 61, 1505-1514.	1.5	65
138	Cellular dedifferentiation of endothelium is linked to activation and silencing of certain nuclear transcription factors: implications for endothelial dysfunction and vascular biology. FASEB Journal, 2000, 14, 740-751.	0.2	64
139	Novel techniques and targets in cardiovascular microRNA research. Cardiovascular Research, 2012, 93, 545-554.	1.8	64
140	Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1273-1280.	1.8	64
141	Circulating microRNAâ€•132 levels improve risk prediction for heart failure hospitalization in patients with chronic heart failure. European Journal of Heart Failure, 2018, 20, 78-85.	2.9	63
142	Proteomic Bioprofiles and Mechanistic Pathways of Progression to Heart Failure. Circulation: Heart Failure, 2019, 12, e005897.	1.6	63
143	Antiandrogenic Therapy With Finasteride Attenuates Cardiac Hypertrophy and Left Ventricular Dysfunction. Circulation, 2015, 131, 1071-1081.	1.6	62
144	Mechanistic Role of Cytochrome P450 Monooxygenases in Oxidized Low-Density Lipoproteinâ€“Induced Vascular Injury. Circulation Research, 2004, 94, e1-13.	2.0	61

#	Article	IF	Citations
145	Clostridium difficile Toxin A Induces Expression of the Stress-induced Early Gene Product RhoB. Journal of Biological Chemistry, 2005, 280, 1499-1505.	1.6	61
146	Chronic miRâ€29 antagonism promotes favorable plaque remodeling in atherosclerotic mice. EMBO Molecular Medicine, 2016, 8, 643-653.	3.3	61
147	miR-21 promotes fibrosis in an acute cardiac allograft transplantation model. Cardiovascular Research, 2016, 110, 215-226.	1.8	61
148	Growth Hormone Treatment Improves Markers of Systemic Nitric Oxide Bioavailability via Insulin-Like Growth Factor-I. Journal of Clinical Endocrinology and Metabolism, 2007, 92, 4172-4179.	1.8	60
149	Review focus on the role of microRNA in cardiovascular biology and disease. Cardiovascular Research, 2012, 93, 543-544.	1.8	60
150	Regulatory RNAs andÂparacrine networks in the heart. Cardiovascular Research, 2014, 102, 290-301.	1.8	60
151	Stiff matrix induces switch to pure Î²-cardiac myosin heavy chain expression in human ESC-derived cardiomyocytes. Basic Research in Cardiology, 2016, 111, 68.	2.5	59
152	Microvesicles as Novel Biomarkers and Therapeutic Targets in Transplantation Medicine. American Journal of Transplantation, 2012, 12, 289-297.	2.6	58
153	Adrenergic Repression of the Epigenetic Reader MeCP2 Facilitates Cardiac Adaptation in Chronic Heart Failure. Circulation Research, 2015, 117, 622-633.	2.0	57
154	Renal effects of guidelineâ€directed medical therapies in heart failure: a consensus document from the Heart Failure <scp>Association of the European Society of Cardiology</scp>. European Journal of Heart Failure, 2022, 24, 603-619.	2.9	57
155	MicroRNA-Mediated Epigenetic Silencing of Sirtuin1 Contributes to Impaired Angiogenic Responses. Circulation Research, 2013, 113, 997-1003.	2.0	56
156	Noncoding RNAs as regulators of cardiomyocyte proliferation and death. Journal of Molecular and Cellular Cardiology, 2015, 89, 59-67.	0.9	56
157	LOX-1 Receptor Blockade Abrogates oxLDL-induced Oxidative DNA Damage and Prevents Activation of the Transcriptional Repressor Oct-1 in Human Coronary Arterial Endothelium. Journal of Biological Chemistry, 2008, 283, 19456-19464.	1.6	55
158	Podocytes regulate the glomerular basement membrane protein nephronectin by means ofÂmiR-378a-3p in glomerular diseases. Kidney International, 2017, 92, 836-849.	2.6	55
159	The XIIIth Banff Conference on Allograft Pathology: The Banff 2015 Heart Meeting Report: Improving Antibody-Mediated Rejection Diagnostics: Strengths, Unmet Needs, and Future Directions. American Journal of Transplantation, 2017, 17, 42-53.	2.6	55
160	Circulating miRNAs as mediators in cell-to-cell communication. Epigenomics, 2019, 11, 111-113.	1.0	55
161	Cytochrome P450 mono-oxygenase gene expression and protein activity in cultures of adult cardiomyocytes of the rat. British Journal of Pharmacology, 2000, 130, 1745-1752.	2.7	54
162	MicroRNAs in diabetes and diabetes-associated complications. RNA Biology, 2012, 9, 820-827.	1.5	54

#	Article	IF	Citations
163	Regulation of cardiac and renal ischemiaâ€"reperfusion injury by microRNAs. Free Radical Biology and Medicine, 2013, 64, 78-84.	1.3	54
164	MicroRNAs and vascular (dys)function. Vascular Pharmacology, 2011, 55, 92-105.	1.0	53
165	Circulating miR-423_5p fails as a biomarker for systemic ventricular function in adults after atrial repair for transposition of the great arteries. International Journal of Cardiology, 2013, 167, 63-66.	0.8	52
166	Activation of the miR-17 Family and miR-21 During Murine Kidney Ischemia-Reperfusion Injury. Nucleic Acid Therapeutics, 2013, 23, 344-354.	2.0	52
167	Circulating <scp>microRNAs</scp> for predicting and monitoring response to mechanical circulatory support from a left ventricular assist device. European Journal of Heart Failure, 2014, 16, 871-879.	2.9	52
168	Impairment of endothelial progenitor cell function and vascularization capacity by aldosterone in mice and humans. European Heart Journal, 2011, 32, 1275-1286.	1.0	51
169	Inflammatory cells and their non-coding RNAs as targets for treating myocardial infarction. Basic Research in Cardiology, 2019, 114, 4.	2.5	51
170	Cardiac dysfunction in cancer patients: beyond direct cardiomyocyte damage of anticancer drugs: novel cardio-oncology insights from the joint 2019 meeting of the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1820-1834.	1.8	51
171	Growth hormone induces eNOS expression and nitric oxide release in a cultured human endothelial cell line. FEBS Letters, 2003, 555, 567-571.	1.3	50
172	Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy. Scientific Reports, 2019, 9, 20350.	1.6	50
173	Acute coronary syndromes and acute heart failure: a diagnostic dilemma and highâ€risk combination. A statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2020, 22, 1298-1314.	2.9	50
174	MicroRNAs in platelet biogenesis and function. Thrombosis and Haemostasis, 2012, 108, 599-604.	1.8	49
175	RNA Profiling in Human and Murine Transplanted Hearts: Identification and Validation of Therapeutic Targets for Acute Cardiac and Renal Allograft Rejection. American Journal of Transplantation, 2016, 16, 99-110.	2.6	49
176	Circulating MicroRNAs Are Not Eliminated by Hemodialysis. PLoS ONE, 2012, 7, e38269.	1.1	48
177	Non-coding RNAs: emerging players in cardiomyocyte proliferation and cardiac regeneration. Basic Research in Cardiology, 2020, 115, 52.	2.5	48
178	Natural Compound Library Screening Identifies New Molecules for the Treatment of Cardiac Fibrosis and Diastolic Dysfunction. Circulation, 2020, 141, 751-767.	1.6	48
179	Omics phenotyping in heart failure: the next frontier. European Heart Journal, 2020, 41, 3477-3484.	1.0	48
180	TWIST1 regulates the activity of ubiquitin proteasome system via the miR-199/214 cluster in human end-stage dilated cardiomyopathy. International Journal of Cardiology, 2013, 168, 1447-1452.	0.8	47

#	Article	IF	Citations
181	Intercellular communication lessons in heart failure. European Journal of Heart Failure, 2015, 17, 1091-1103.	2.9	47
182	MicroRNA-Based Therapy of GATA2-Deficient Vascular Disease. Circulation, 2016, 134, 1973-1990.	1.6	46
183	Functional MicroRNA Library Screening Identifies the HypoxaMiR MiR-24 as a Potent Regulator of Smooth Muscle Cell Proliferation and Vascularization. Antioxidants and Redox Signaling, 2014, 21, 1167-1176.	2.5	44
184	Methods for the identification and characterization of extracellular vesicles in cardiovascular studies: from exosomes to microvesicles. Cardiovascular Research, 2023, 119, 45-63.	1.8	44
185	No effects of human ghrelin on cardiac function despite profound effects on body composition in a rat model of heart failure. International Journal of Cardiology, 2009, 137, 267-275.	0.8	42
186	Endothelial Progenitor Cells in Pulmonary Arterial Hypertension. Trends in Cardiovascular Medicine, 2010, 20, 22-29.	2.3	41
187	Deciphering the microRNA signature of pathological cardiac hypertrophy by engineered heart tissue- and sequencing-technology. Journal of Molecular and Cellular Cardiology, 2015, 81, 1-9.	0.9	41
188	Non-coding RNAs as modulators of the cardiac fibroblast phenotype. Journal of Molecular and Cellular Cardiology, 2016, 92, 75-81.	0.9	41
189	Circulating Long Noncoding RNA LIPCAR Predicts Heart Failure Outcomes in Patients Without Chronic Kidney Disease. Hypertension, 2019, 73, 820-828.	1.3	41
190	AntimiR-132 Attenuates Myocardial Hypertrophy in an Animal Model of Percutaneous Aortic Constriction. Journal of the American College of Cardiology, 2021, 77, 2923-2935.	1.2	41
191	Functional Genomics of Cardioprotection by Ischemic Conditioning and the Influence of Comorbid Conditions: Implications in Target Identification. Current Drug Targets, 2015, 16, 904-911.	1.0	41
192	A circular RNA derived from the insulin receptor locus protects against doxorubicin-induced cardiotoxicity. European Heart Journal, 2022, 43, 4496-4511.	1.0	41
193	Deregulation of microRNA-181c in cerebrospinal fluid of patients with clinically isolated syndrome is associated with early conversion to relapsingâ€“remitting multiple sclerosis. Multiple Sclerosis Journal, 2016, 22, 1202-1214.	1.4	40
194	Increased Proangiogenic Activity of Mobilized CD34 ⁺ Progenitor Cells of Patients With Acute ST-Segmentâ€“Elevation Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 341-349.	1.1	40
195	Sonic hedgehog-dependent activation of adventitial fibroblasts promotes neointima formation. Cardiovascular Research, 2017, 113, 1653-1663.	1.8	40
196	Renal AAV2-Mediated Overexpression of Long Non-Coding RNA H19 Attenuates Ischemic Acute Kidney Injury Through Sponging of microRNA-30a-5p. Journal of the American Society of Nephrology: JASN, 2021, 32, 323-341.	3.0	40
197	Non-coding RNAs in cardiovascular ageing. Ageing Research Reviews, 2014, 17, 79-85.	5.0	39
198	Noncoding RNAs in Heart Failure. Handbook of Experimental Pharmacology, 2016, 243, 423-445.	0.9	39

#	Article	IF	Citations
199	Non-coding RNAs: update on mechanisms and therapeutic targets from the ESC Working Groups of Myocardial Function and Cellular Biology of the Heart. Cardiovascular Research, 2020, 116, 1805-1819.	1.8	39
200	Induction of nuclear transcription factors, cytochrome P450 monooxygenases, and glutathione S-transferase alpha gene expression in Aroclor 1254-treated rat hepatocyte cultures11Abbreviations: Ah, aryl hydrocarbon; c/EBP, CCAAT/enhancer-binding protein; cDNA, complementary DNA CYP, cytochrome P450; EROD, ethoxyresorufin-O-deethylase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GSTA, glutathione S-transferase alpha; HNF, hepatic nuclear factor; RTâ€"PCR, reverse transcriptionâ€"polymerase chain reaction; and. Biochemical Pharmacology, 2001, 61, 145-153.	2.0	38
201	miR-212/132 Cluster Modulation Prevents Doxorubicin-Mediated Atrophy and Cardiotoxicity. Molecular Therapy, 2019, 27, 17-28.	3.7	38
202	Microparticles and microRNAs of endothelial progenitor cells ameliorate acute kidney injury. Kidney International, 2012, 82, 375-377.	2.6	37
203	LINCing MALAT1 and Angiogenesis. Circulation Research, 2014, 114, 1366-1368.	2.0	37
204	Zinc-Î±2-Glycoprotein Exerts Antifibrotic Effects in Kidney and Heart. Journal of the American Society of Nephrology: JASN, 2015, 26, 2659-2668.	3.0	37
205	Long Noncoding RNAs in Pathological Cardiac Remodeling. Circulation Research, 2017, 120, 262-264.	2.0	37
206	Non-coding RNAs in vascular disease â€" from basic science to clinical applications: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology. Cardiovascular Research, 2018, 114, 1281-1286.	1.8	37
207	Risk stratification and management of women with cardiomyopathy/heart failure planning pregnancy or presenting during/after pregnancy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on Peripartum Cardiomyopathy. European Journal of Heart Failure, 2021, 23, 527-540.	2.9	37
208	Pathophysiology of <scp>T</scp>akotsubo syndromeÂâ€"Âa joint scientific statement from the Heart Failure Association <scp>T</scp>akotsubo Syndrome Study Group and Myocardial Function Working Group of the <scp>E</scp>uropean Society of CardiologyÂâ€"ÂPart 1: overview and the central role for catecholamines and sympathetic nervous system. European Journal of Heart Failure, 2022, 24, 257-273.	2.9	36
209	Cardiomyocyte ageing and cardioprotection: consensus document from the ESC working groups cell biology of the heart and myocardial function. Cardiovascular Research, 2020, 116, 1835-1849.	1.8	34
210	Leveraging clinical epigenetics in heart failure with preserved ejection fraction: a call for individualized therapies. European Heart Journal, 2021, 42, 1940-1958.	1.0	34
211	Pathophysiology of Takotsubo syndromeÂâ€" a joint scientific statement from the Heart Failure Association Takotsubo Syndrome Study Group and Myocardial Function Working Group of the European Society of CardiologyÂâ€"ÂPart 2: vascular pathophysiology, gender and sex hormones, genetics, chronic cardiovascular problems and clinical implications. European Journal of Heart Failure, 2022, 24, 274-286.	2.9	34
212	Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease. International Journal of Cardiology, 2012, 156, 289-294.	0.8	33
213	Aromatase Inhibition Attenuates Desflurane-Induced Preconditioning against Acute Myocardial Infarction in Male Mouse Heart In Vivo. PLoS ONE, 2012, 7, e42032.	1.1	33
214	Porcine model of progressive cardiac hypertrophy and fibrosis with secondary postcapillary pulmonary hypertension. Journal of Translational Medicine, 2017, 15, 202.	1.8	33
215	MicroRNAs As Circulating Biomarkers for Heart Failure: Questions About MiR-423-5p. Circulation Research, 2010, 106, e8; author reply e9.	2.0	32
216	Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy. American Journal of Physiology - Heart and Circulatory Physiology, 2016, 311, H707-H712.	1.5	32

#	Article	IF	Citations
217	Regulator of G-Protein Signaling 5 Prevents Smooth Muscle Cell Proliferation and Attenuates Neointima Formation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 317-327.	1.1	32
218	MicroRNAs regulating superoxide dismutase 2 are new circulating biomarkers of heart failure. Scientific Reports, 2017, 7, 14747.	1.6	32
219	MicroRNA 628-5p as a Novel Biomarker for Cardiac Allograft Vasculopathy. Transplantation, 2017, 101, e26-e33.	0.5	32
220	Chronic kidney disease induces left ventricular overexpression of the pro-hypertrophic microRNA-212. Scientific Reports, 2019, 9, 1302.	1.6	32
221	<scp>MiRNA</scp>â€•181a is a novel regulator of aldosteroneâ€"mineralocorticoid receptorâ€•mediated cardiac remodelling. European Journal of Heart Failure, 2020, 22, 1366-1377.	2.9	32
222	<scp>COVID</scp>â€•19 vaccination in patients with heart failure: a position paper of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2021, 23, 1806-1818.	2.9	32
223	miR-486 attenuates cardiac ischemia/reperfusion injury and mediates the beneficial effect of exercise for myocardial protection. Molecular Therapy, 2022, 30, 1675-1691.	3.7	32
224	Interpretation and actionability of genetic variants in cardiomyopathies: a position statement from the European Society of Cardiology Council on cardiovascular genomics. European Heart Journal, 2022, 43, 1901-1916.	1.0	32
225	Telomerase therapy attenuates cardiotoxic effects of doxorubicin. Molecular Therapy, 2021, 29, 1395-1410.	3.7	31
226	miR-21, Mediator, and Potential Therapeutic Target in the Cardiorenal Syndrome. Frontiers in Pharmacology, 2020, 11, 726.	1.6	31
227	Cardiac Fibrosis Revisited by MicroRNA Therapeutics. Circulation, 2012, 126, 800-802.	1.6	30
228	SARS-CoV-2 receptor ACE2 expression in the human heart: cause of a post-pandemic wave of heart failure?. European Heart Journal, 2020, 41, 1807-1809.	1.0	30
229	Circulating microRNAs predispose to takotsubo syndrome following high-dose adrenaline exposure. Cardiovascular Research, 2022, 118, 1758-1770.	1.8	30
230	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	1.8	30
231	Verapamil: identification of novel metabolites in cultures of primary human hepatocytes and human urine by LC-MS n and LC-NMR. Xenobiotica, 2003, 33, 655-676.	0.5	29
232	Resident cardiac macrophages: crucial modulators of cardiac (patho)physiology. Basic Research in Cardiology, 2020, 115, 77.	2.5	29
233	Pharmacokinetics and Proceedings in Clinical Application of Nucleic Acid Therapeutics. Molecular Therapy, 2021, 29, 521-539.	3.7	29
234	Heart Failure Association, Heart Failure Society of America, and Japanese Heart Failure Society Position Statement on Endomyocardial Biopsy. Journal of Cardiac Failure, 2021, 27, 727-743.	0.7	29

#	Article	IF	Citations
235	Cardiac remodellingÂâ€"ÂPart 1: From cells and tissues to circulating biomarkers. A review from the Study Group on Biomarkers of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 927-943.	2.9	29
236	A rapid and simple CYP2D6 genotyping assayâ€"case study with the analgetic tramadol. Metabolism: Clinical and Experimental, 2003, 52, 1439-1443.	1.5	27
237	VERAPAMIL: METABOLISM IN CULTURES OF PRIMARY HUMAN CORONARY ARTERIAL ENDOTHELIAL CELLS. Drug Metabolism and Disposition, 2003, 31, 888-891.	1.7	27
238	Detection of early signals of hepatotoxicity by gene expression profiling studies with cultures of metabolically competent human hepatocytes. Archives of Toxicology, 2008, 82, 89-101.	1.9	27
239	MicroRNAs in the bile of patients with biliary strictures after liver transplantation. Liver Transplantation, 2014, 20, 673-678.	1.3	27
240	New Insights Into miR-17â€"92 Cluster Regulation and Angiogenesis. Circulation Research, 2016, 118, 9-11.	2.0	27
241	Remote Welfare Monitoring of Rodents Using Thermal Imaging. Sensors, 2018, 18, 3653.	2.1	27
242	Reciprocal organ interactions during heart failure: a position paper from the ESC Working Group on Myocardial Function. Cardiovascular Research, 2021, 117, 2416-2433.	1.8	27
243	Skeletal muscle derived Musclin protects the heart during pathological overload. Nature Communications, 2022, 13, 149.	5.8	27
244	MicroRNAs in right ventricular remodelling. Cardiovascular Research, 2017, 113, 1433-1440.	1.8	26
245	miRNome Profiling of Purified Endoderm and Mesoderm Differentiated from hESCs Reveals Functions of miR-483-3p and miR-1263 for Cell-Fate Decisions. Stem Cell Reports, 2017, 9, 1588-1603.	2.3	26
246	Nonâ€coding RNAs: key players in cardiac disease. Journal of Physiology, 2020, 598, 2995-3003.	1.3	26
247	Metabolism of verapamil: 24 new phase I and phase II metabolites identified in cell cultures of rat hepatocytes by liquid chromatographyâ€"tandem mass spectrometry. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2003, 798, 265-274.	1.2	25
248	MicroRNAs in the broken heart. European Journal of Clinical Investigation, 2007, 37, 829-833.	1.7	25
249	Role of microRNAs in immunity and organ transplantation. Expert Reviews in Molecular Medicine, 2011, 13, e37.	1.6	25
250	Antagonism of profibrotic microRNA-21 improvesÂoutcome of murine chronic renal allograft dysfunction. Kidney International, 2017, 92, 646-656.	2.6	25
251	A large shRNA library approach identifies lncRNA Ntep as an essential regulator of cell proliferation. Cell Death and Differentiation, 2018, 25, 307-318.	5.0	25
252	Living myocardial slices: a novel multicellular model for cardiac translational research. European Heart Journal, 2020, 41, 2405-2408.	1.0	25

#	Article	IF	Citations
253	MicroRNAs in platelet physiology and pathology. Hamostaseologie, 2013, 33, 17-20.	0.9	24
254	Remodelling of adult cardiac tissue subjected to physiological and pathological mechanical load <i>in vitro</i>. Cardiovascular Research, 2022, 118, 814-827.	1.8	24
255	Verapamil: new insight into the molecular mechanism of drug oxidation in the human heart. Journal of Chromatography A, 2002, 970, 117-130.	1.8	23
256	Aroclor 1254 Modulates Gene Expression of Nuclear Transcription Factors: Implications for Albumin Gene Transcription and Protein Synthesis in Rat Hepatocyte Cultures. Toxicology and Applied Pharmacology, 2002, 181, 79-88.	1.3	23
257	GCâ€“MS assay for hepatic DDAH activity in diabetic and non-diabetic rats by measuring dimethylamine (DMA) formed from asymmetric dimethylarginine (ADMA): Evaluation of the importance of S-nitrosothiols as inhibitors of DDAH activity in vitro and in vivo in humans. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 858, 32-41.	1.2	23
258	Non-coding RNAs as orchestrators of autophagic processes. Journal of Molecular and Cellular Cardiology, 2016, 95, 26-30.	0.9	23
259	Aging impairs alveolar epithelial type II cell function in acute lung injury. American Journal of Physiology - Lung Cellular and Molecular Physiology, 2020, 319, L755-L769.	1.3	23
260	Association between Circular RNA CDR1as and Post-Infarction Cardiac Function in Pig Ischemic Heart Failure: Influence of the Anti-Fibrotic Natural Compounds Bufalin and Lycorine. Biomolecules, 2020, 10, 1180.	1.8	23
261	Inflammatory Drivers of Cardiovascular Disease: Molecular Characterization of Senescent Coronary Vascular Smooth Muscle Cells. Frontiers in Physiology, 2020, 11, 520.	1.3	23
262	Increase of Pro-Inflammatory Cytokine Expression in Non-Demyelinating Early Cerebral Lesions in Nervous Canine Distemper. Viral Immunology, 2008, 21, 401-410.	0.6	22
263	miRNAs involved in the generation, maintenance, and differentiation of pluripotent cells. Journal of Molecular Medicine, 2012, 90, 747-752.	1.7	22
264	MicroRNAs in Right Ventricular (dys)function (2013 Grover Conference Series). Pulmonary Circulation, 2014, 4, 185-190.	0.8	22
265	Circulating Long Noncoding RNAs in Personalized Medicine. Journal of the American College of Cardiology, 2016, 68, 2914-2916.	1.2	22
266	Stimulating pro-reparative immune responses to prevent adverse cardiac remodelling: consensus document from the joint 2019 meeting of the ESC Working Groups of cellular biology of the heart and myocardial function. Cardiovascular Research, 2020, 116, 1850-1862.	1.8	22
267	Targeted therapies in genetic dilated and hypertrophic cardiomyopathies: from molecular mechanisms to therapeutic targets. A position paper from the Heart Failure Association (HFA) and the Working Group on Myocardial Function of the European Society of Cardiology (ESC). European Journal of Heart Failure, 2022, 24, 406-420.	2.9	22
268	Rationale of the FIBROTARGETS study designed to identify novel biomarkers of myocardial fibrosis. ESC Heart Failure, 2018, 5, 139-148.	1.4	21
269	Circulating miR-1254 predicts ventricular remodeling in patients with ST-Segment-Elevation Myocardial Infarction: A cardiovascular magnetic resonance study. Scientific Reports, 2018, 8, 15115.	1.6	21
270	Blood-based microRNA profiling in patients with cardiac amyloidosis. PLoS ONE, 2018, 13, e0204235.	1.1	21

#	Article	IF	Citations
271	Selective Heart Irradiation Induces Cardiac Overexpression of the Pro-hypertrophic miR-212. Frontiers in Oncology, 2019, 9, 598.	1.3	21
272	PCBs alter gene expression of nuclear transcription factors and other heart-specific genes in cultures of primary cardiomyocytes: possible implications for cardiotoxicity. Xenobiotica, 2002, 32, 1173-1183.	0.5	20
273	Cardiac Dissonance Without Conductors. Circulation, 2008, 118, 1524-1527.	1.6	20
274	Bioinformatics of cardiovascular miRNA biology. Journal of Molecular and Cellular Cardiology, 2015, 89, 3-10.	0.9	20
275	Inhibition of miRNA-212/132 improves the reprogramming of fibroblasts into induced pluripotent stem cells by de-repressing important epigenetic remodelling factors. Stem Cell Research, 2017, 20, 70-75.	0.3	20
276	In peripartum cardiomyopathy plasminogen activator inhibitor-1 is a potential new biomarker with controversial roles. Cardiovascular Research, 2020, 116, 1875-1886.	1.8	20
277	Assessment of major mental disorders in a German peripartum cardiomyopathy cohort. ESC Heart Failure, 2020, 7, 4394-4398.	1.4	20
278	Overexpression of preeclampsia induced microRNA-26a-5p leads to proteinuria in zebrafish. Scientific Reports, 2018, 8, 3621.	1.6	19
279	A novel multi-parametric analysis of non-invasive methods to assess animal distress during chronic pancreatitis. Scientific Reports, 2019, 9, 14084.	1.6	19
280	Circulating microRNAs in Fabry Disease. Scientific Reports, 2019, 9, 15277.	1.6	19
281	Butanedione Monoxime Increases the Viability and Yield of Adult Cardiomyocytes in Primary Cultures. Cardiovascular Toxicology, 2001, 1, 61-72.	1.1	18
282	Endothelial progenitor cell dysfunction: mechanisms and therapeutic approaches. European Journal of Clinical Investigation, 2007, 37, 603-606.	1.7	18
283	Heterocellular signalling and crosstalk in the heart in ischaemia and heart failure. Cardiovascular Research, 2014, 102, 191-193.	1.8	18
284	Circulating miR-21 and miR-29a as Markers of Disease Severity and Etiology in Cholestatic Pediatric Liver Disease. Journal of Clinical Medicine, 2016, 5, 28.	1.0	18
285	Improved cardiovascular risk prediction in patients with end-stage renal disease on hemodialysis using machine learning modeling and circulating microribonucleic acids. Theranostics, 2020, 10, 8665-8676.	4.6	18
286	miRâ^'21 and NT-proBNP Correlate with Echocardiographic Parameters of Atrial Dysfunction and Predict Atrial Fibrillation. Journal of Clinical Medicine, 2020, 9, 1118.	1.0	18
287	Novel aspects of age-protection by spermidine supplementation are associated with preserved telomere length. GeroScience, 2021, 43, 673-690.	2.1	18
288	The Smooth Long Noncoding RNA SENCR. Arteriosclerosis, Thrombosis, and Vascular Biology, 2014, 34, 1124-1125.	1.1	17

#	Article	IF	Citations
289	Endothelial function in contemporary patients with repaired coarctation of aorta. Heart, 2014, 100, 1696-1701.	1.2	17
290	<scp>TIP</scp> 30 counteracts cardiac hypertrophy and failure by inhibiting translational elongation. EMBO Molecular Medicine, 2019, 11, e10018.	3.3	17
291	Integrative Bioinformatic Analyses of Global Transcriptome Data Decipher Novel Molecular Insights into Cardiac Anti-Fibrotic Therapies. International Journal of Molecular Sciences, 2020, 21, 4727.	1.8	17
292	Cardiovascular RNA markers and artificial intelligence may improve COVID-19 outcome: a position paper from the EU-CardioRNA COST Action CA17129. Cardiovascular Research, 2021, 117, 1823-1840.	1.8	17
293	Enabling [¹⁸F]-bicyclo[6.1.0]nonyne for oligonucleotide conjugation for positron emission tomography applications: [¹⁸F]-anti-microRNA-21 as an example. Chemical Communications, 2015, 51, 9821-9824.	2.2	16
294	Identification of cell and disease specific microRNAs in glomerular pathologies. Journal of Cellular and Molecular Medicine, 2019, 23, 3927-3939.	1.6	16
295	Noncoding RNAs: potential regulators in cardioncology. American Journal of Physiology - Heart and Circulatory Physiology, 2019, 316, H160-H168.	1.5	16
296	A 3D iPSC-differentiation model identifies interleukin-3 as a regulator of early human hematopoietic specification. Haematologica, 2021, 106, 1354-1367.	1.7	16
297	Dissecting the transcriptome in cardiovascular disease. Cardiovascular Research, 2022, 118, 1004-1019.	1.8	16
298	TLR-4+ peripheral blood monocytes and cardiovascular events in patients with chronic kidney disease--a prospective follow-up study. Nephrology Dialysis Transplantation, 2011, 26, 1421-1424.	0.4	15
299	Elevated levels of miR-181c and miR-633 in the CSF of patients with MS. Neurology: Neuroimmunology and NeuroInflammation, 2019, 6, e623.	3.1	15
300	A practical guide for investigating cardiac physiology using living myocardial slices. Basic Research in Cardiology, 2020, 115, 61.	2.5	15
301	Cardiac endurance training alters plasma profiles of circular RNA MBOAT2. American Journal of Physiology - Heart and Circulatory Physiology, 2020, 319, H13-H21.	1.5	15
302	The IGF-1 Receptor as a Therapeutic Target to Improve Endothelial Progenitor Cell Function. Molecular Medicine, 2008, 14, 235-237.	1.9	14
303	Organic Nitrates Differentially Modulate Circulating Endothelial Progenitor Cells and Endothelial Function in Patients with Symptomatic Coronary Artery Disease. Antioxidants and Redox Signaling, 2011, 15, 925-931.	2.5	14
304	Identification of cardiovascular microRNA targetomes. Journal of Molecular and Cellular Cardiology, 2011, 51, 674-681.	0.9	14
305	Analytical approaches in microRNA therapeutics. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 964, 146-152.	1.2	14
306	Facts and updates about cardiovascular nonâ€coding RNAs in heart failure. ESC Heart Failure, 2015, 2, 108-111.	1.4	14

#	Article	IF	Citations
307	Effects of personalized endurance training on cellular age and vascular function in middle-aged sedentary women. European Journal of Preventive Cardiology, 2019, 26, 1903-1906.	0.8	14
308	Genomic instability in the naturally and prematurely aged myocardium. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	14
309	Identification of Major CYP2C9 and CYP2C19 Polymorphisms by Fluorescence Resonance Energy Transfer Analysis. Clinical Chemistry, 2002, 48, 1592-1594.	1.5	13
310	Linc- ing the Noncoding Genome to Heart Function: Beating Hypertrophy. Trends in Molecular Medicine, 2017, 23, 577-579.	3.5	13
311	Identification of miRâ€126 as a new regulator of skin ageing. Experimental Dermatology, 2017, 26, 284-286.	1.4	13
312	Alternative strategies in cardiac preclinical research and new clinical trial formats. Cardiovascular Research, 2022, 118, 746-762.	1.8	13
313	Biomarkers for the prediction of heart failure and cardiovascular events in patients with type 2 diabetes: a position statement from the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 2022, 24, 1162-1170.	2.9	13
314	Microarray-based gene expression profiling to elucidate cellular responses to nitric oxideâ€"A review from an analytical and biomedical point of view. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2007, 851, 3-11.	1.2	12
315	Breakthrough in cachexia treatment through a novel selective androgen receptor modulator?!. Journal of Cachexia, Sarcopenia and Muscle, 2011, 2, 121-123.	2.9	12
316	miRNAGE-34 induces cardiac damAGE. Cell Research, 2013, 23, 866-867.	5.7	12
317	MicroRNA-based therapy in cardiology. Herz, 2014, 39, 194-200.	0.4	12
318	Therapeutic modulation of RNA-binding protein Rbm38 facilitates re-endothelialization after arterial injury. Cardiovascular Research, 2019, 115, 1804-1810.	1.8	12
319	Pleiotropic cardiac functions controlled by ischemia-induced lncRNA H19. Journal of Molecular and Cellular Cardiology, 2020, 146, 43-59.	0.9	12
320	ERBB4 and Multiple MicroRNAs That Target ERBB4 Participate in Pregnancy-Related Cardiomyopathy. Circulation: Heart Failure, 2021, 14, e006898.	1.6	12
321	The long non-coding RNA NRON promotes the development of cardiac hypertrophy in the murine heart. Molecular Therapy, 2022, 30, 1265-1274.	3.7	12
322	REPROGRAMMING OF GENE EXPRESSION IN CULTURED CARDIOMYOCYTES AND IN EXPLANTED HEARTS BY THE MYOSIN ATPASE INHIBITOR BUTANEDIONE MONOXIME. Transplantation, 2001, 71, 543-552.	0.5	11
323	MicroRNAâ€Based Therapeutic Approaches in the Cardiovascular System. Cardiovascular Therapeutics, 2012, 30, e9-e15.	1.1	11
324	MicroRNAs in vascular biology â€" metabolism and atherosclerosis. Thrombosis and Haemostasis, 2012, 107, 603-604.	1.8	11

#	Article	IF	Citations
325	<scp>ESC</scp> Working Group on Myocardial Function Position Paper: how to study the right ventricle in experimental models. European Journal of Heart Failure, 2014, 16, 509-518.	2.9	11
326	Leukocyte telomere length correlates with hypertrophic cardiomyopathy severity. Scientific Reports, 2018, 8, 11227.	1.6	11
327	Comprehensive Bioinformatics Identifies Key microRNA Players in ATG7-Deficient Lung Fibroblasts. International Journal of Molecular Sciences, 2020, 21, 4126.	1.8	11
328	Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion. Biomedicine Hub, 2020, 5, 1-23.	0.4	11
329	Verapamil metabolism in distinct regions of the heart and in cultures of cardiomyocytes of adult rats. Drug Metabolism and Disposition, 2001, 29, 761-8.	1.7	11
330	AAV capsid engineering identified two novel variants with improved inÂvivo tropism for cardiomyocytes. Molecular Therapy, 2022, 30, 3601-3618.	3.7	11
331	Isolation and cultivation of Ca2+tolerant cardiomyocytes from the adult rat: improvements and applications. Xenobiotica, 2000, 30, 1063-1077.	0.5	10
332	Endothelial Progenitor Cells as Potential Drug Targets. Current Drug Targets Cardiovascular & Haematological Disorders, 2005, 5, 277-286.	2.0	10
333	Impact of a Met(11)Thr single nucleotide polymorphism of surfactant protein D on allergic airway inflammation in a murine asthma model. Experimental Lung Research, 2014, 40, 154-163.	0.5	10
334	Epigenetic modulation of vascular diseases: Assessing the evidence and exploring the opportunities. Vascular Pharmacology, 2018, 107, 43-52.	1.0	10
335	Non-coding RNAs: Regulators of valvular calcification. Journal of Molecular and Cellular Cardiology, 2020, 142, 14-23.	0.9	10
336	Combined high-throughput library screening and next generation RNA sequencing uncover microRNAs controlling human cardiac fibroblast biology. Journal of Molecular and Cellular Cardiology, 2021, 150, 91-100.	0.9	10
337	Perspective review of optical imaging in welfare assessment in animal-based research. Journal of Biomedical Optics, 2019, 24, 1.	1.4	10
338	miR-625-3p is upregulated in CD8+ T cells during early immune reconstitution after allogeneic stem cell transplantation. PLoS ONE, 2017, 12, e0183828.	1.1	10
339	Cardiac Fibroblast Growth Factor 23 Excess Does Not Induce Left Ventricular Hypertrophy in Healthy Mice. Frontiers in Cell and Developmental Biology, 2021, 9, 745892.	1.8	10
340	ANDROGEN METABOLISM IN THYMUS OF FETAL AND ADULT RATS. Drug Metabolism and Disposition, 2004, 32, 675-679.	1.7	9
341	Measurement and diagnostic use of hepatic cytochrome P450 metabolism of oleic acid in liver disease. Liver International, 2010, 30, 1181-1188.	1.9	9
342	Circulating microRNAs in Patients with Shiga-Toxin-Producing E. coli O104:H4 Induced Hemolytic Uremic Syndrome. PLoS ONE, 2012, 7, e47215.	1.1	9

#	Article	IF	Citations
343	Diagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 653-660.	0.4	9
344	LIPCAR Is Increased in Chronic Symptomatic HF Patients. A Sub-Study of the GISSI-HF Trial. Clinical Chemistry, 2021, 67, 1721-1731.	1.5	9
345	miR-21-KO Alleviates Alveolar Structural Remodeling and Inflammatory Signaling in Acute Lung Injury. International Journal of Molecular Sciences, 2020, 21, 822.	1.8	9
346	Non-coding RNAs: key regulators of reprogramming, pluripotency, and cardiac cell specification with therapeutic perspective for heart regeneration. Cardiovascular Research, 2022, 118, 3071-3084.	1.8	9
347	Spotlight on endothelial progenitor cell inhibitors: short review. Vascular Medicine, 2005, 10, S59-S64.	0.8	8
348	Spotlight on endothelial progenitor cell inhibitors: short review. Vascular Medicine, 2005, 10, S59-S64.	0.8	8
349	Obesity and risk of myocardial infarction: the INTERHEART study. Lancet, The, 2006, 367, 1051-1052.	6.3	8
350	Nutritional iron deficiency in patients with chronic illnesses. Lancet, The, 2007, 370, 1906.	6.3	8
351	Liraglutide for weight loss in obese people. Lancet, The, 2010, 375, 551-552.	6.3	8
352	Conversion from conventional in-centre thrice-weekly haemodialysis to short daily home haemodialysis ameliorates uremia-associated clinical parameters. International Urology and Nephrology, 2012, 44, 883-890.	0.6	8
353	MicroRNA Target Sites as Genetic Tools to Enhance Promoter-Reporter Specificity for the Purification of Pancreatic Progenitor Cells from Differentiated Embryonic Stem Cells. Stem Cell Reviews and Reports, 2013, 9, 555-568.	5.6	8
354	Pathologic endothelial response and impaired function of circulating angiogenic cells in patients with Fabry disease. Basic Research in Cardiology, 2013, 108, 311.	2.5	8
355	Inhibition of proteasomeâ€mediated glucocorticoid receptor degradation restores nitric oxide bioavailability in myocardial endothelial cells <i>in vitro</i>. Biology of the Cell, 2014, 106, 219-235.	0.7	8
356	LCâ€“MS/MS and GCâ€“MS/MS measurement of plasma and urine di-paracetamol and 3-nitro-paracetamol: Proof-of-concept studies on a novel human model of oxidative stress based on oral paracetamol administration. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 959, 71-81.	1.2	8
357	Non-coding RNAs in ageing. Ageing Research Reviews, 2014, 17, 1-2.	5.0	8
358	CircSlc8a1, breaking a vicious circle in cardiac hypertrophy. Cardiovascular Research, 2019, 115, 1946-1947.	1.8	8
359	Identification of miR-143 as a Major Contributor for Human Stenotic Aortic Valve Disease. Journal of Cardiovascular Translational Research, 2019, 12, 447-458.	1.1	8
360	Blood-based protein profiling identifies serum protein c-KIT as a novel biomarker for hypertrophic cardiomyopathy. Scientific Reports, 2021, 11, 1755.	1.6	8

#	Article	IF	Citations
361	Remote vitals monitoring in rodents using video recordings. Biomedical Optics Express, 2019, 10, 4422.	1.5	8
362	Artificial Intelligence Identifies an Urgent Need for Peripheral Vascular Intervention by Multiplexing Standard Clinical Parameters. Biomedicines, 2021, 9, 1456.	1.4	8
363	Development and characterization of anti-fibrotic natural compound similars with improved effectivity. Basic Research in Cardiology, 2022, 117, 9.	2.5	8
364	ADMA, Endothelial Progenitor Cells, and Cardiovascular Risk. Circulation Research, 2005, 97, .	2.0	7
365	Cardiac fibroblasts on the fast track â€“. Journal of Molecular and Cellular Cardiology, 2009, 47, 174-176.	0.9	7
366	Changing Direction. Circulation Research, 2017, 120, 1393-1395.	2.0	7
367	Circulating non-coding RNAs as biomarkers to predict and monitor the response to exercise: chances and hurdles. European Heart Journal, 2018, 39, 3552-3552.	1.0	7
368	Leptin Expression and Gene Methylation Patterns in Alcohol-Dependent Patients with Ethyltoxic Cirrhosisâ€"Normalization After Liver Transplantation and Implications for Future Research. Alcohol and Alcoholism, 2018, 53, 511-517.	0.9	7
369	Circulating miR-216a as a biomarker of metabolic alterations and obesity in women. Non-coding RNA Research, 2020, 5, 144-152.	2.4	7
370	Role of endothelial microRNA 155 on capillary leakage in systemic inflammation. Critical Care, 2021, 25, 76.	2.5	7
371	Trapping of NAPQI, the intermediate toxic paracetamol metabolite, by aqueous sulfide (S2â^') and analysis by GCâ€"MS/MS. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2014, 963, 99-105.	1.2	6
372	The Long Non-coding RNA Cyrano Is Dispensable for Pluripotency of Murine and Human Pluripotent Stem Cells. Stem Cell Reports, 2020, 15, 13-21.	2.3	6
373	Education and certification on heart failure of the <scp>H</scp>eart <scp>F</scp>ailure <scp>A</scp>ssociation of the <scp>E</scp>uropean <scp>S</scp>ociety of <scp>C</scp>ardiology. European Journal of Heart Failure, 2022, 24, 249-253.	2.9	6
374	Growth hormone regulates vascular functionâ€"what we know from bench and bedside. European Journal of Clinical Pharmacology, 2006, 62, 29-32.	0.8	5
375	MicroRNAs in Idiopathic Childhood Nephrotic Syndrome. Clinical Chemistry, 2013, 59, 595-597.	1.5	5
376	State-of-the-art on non-coding RNA bioinformatics, diagnostics and therapeutics in cardiovascular diseases. Journal of Molecular and Cellular Cardiology, 2015, 89, 1-2.	0.9	5
377	Long Noncoding RNAs as Inducers and Terminators of Vascular Development. Circulation, 2015, 131, 1236-1238.	1.6	5
378	microRNA-206 correlates with left ventricular function after transcatheter aortic valve implantation. American Journal of Physiology - Heart and Circulatory Physiology, 2017, 313, H1261-H1266.	1.5	5

#	Article	IF	Citations
379	Translational Opportunities and Challenges of Long Noncoding RNAs inÂCardiac Regeneration. Journal of the American College of Cardiology, 2018, 72, 551-552.	1.2	5
380	Studying Interactions between 2â€™-O-Me-Modified Inhibitors and MicroRNAs Utilizing Microscale Thermophoresis. Molecular Therapy - Nucleic Acids, 2019, 18, 259-268.	2.3	5
381	Long non-coding RNAs: A crucial part of the vasculature puzzle. Vascular Pharmacology, 2019, 114, 131-138.	1.0	5
382	A comprehensive method protocol for annotation and integrated functional understanding of lncRNAs. Briefings in Bioinformatics, 2020, 21, 1391-1396.	3.2	5
383	MicroRNAs as systemic biomarkers to assess distress in animal models for gastrointestinal diseases. Scientific Reports, 2020, 10, 16931.	1.6	5
384	Reply to â€˜<scp>COVID</scp>â€19 severity, <scp>miR</scp>â€21 targets, and common human genetic variationâ€™. European Journal of Heart Failure, 2021, 23, 1987-1988.	2.9	5
385	Circulating miR-185-5p as a Potential Biomarker for Arrhythmogenic Right Ventricular Cardiomyopathy. Cells, 2021, 10, 2578.	1.8	5
386	DGK and DZHK position paper on genome editing: basic science applications and future perspective. Basic Research in Cardiology, 2021, 116, 2.	2.5	5
387	Identification of major CYP2C9 and CYP2C19 polymorphisms by fluorescence resonance energy transfer analysis. Clinical Chemistry, 2002, 48, 1592-4.	1.5	5
388	Exercise-Induced Long Noncoding RNAs As New Players in Cardiac Hypertrophy. Circulation, 2022, 145, 1234-1237.	1.6	5
389	Cardiac regeneration by progenitor cells - bedside before bench?. European Journal of Clinical Investigation, 2005, 35, 417-420.	1.7	4
390	Limitations of Gait Speed as an Independent Predictor of Mortality and Morbidity in Cardiac Patients. Journal of the American College of Cardiology, 2011, 58, 776.	1.2	4
391	Novel nonâ€coding RNAâ€based therapeutic approaches to prevent statinâ€induced liver damage. EMBO Molecular Medicine, 2012, 4, 863-865.	3.3	4
392	TGF-Î² Inhibitor CILP as a Novel Biomarker for Cardiac Fibrosis. JACC Basic To Translational Science, 2020, 5, 444-446.	1.9	4
393	Serum microRNAs and antifibrotic response to eplerenone in acute myocardial infarction complicated by systolic dysfunction. International Journal of Cardiology, 2021, 332, 35-37.	0.8	4
394	Prognostic value of circulating microRNAs compared to high-sensitivity troponin T in patients presenting with suspected acute coronary syndrome to the emergency department. Clinical Biochemistry, 2022, 99, 9-16.	0.8	4
395	Neonatal injury models: integral tools to decipher the molecular basis of cardiac regeneration. Basic Research in Cardiology, 2022, 117, 26.	2.5	4
396	Mobilization of bone marrow-derived stem cells after myocardial infarction and left ventricular function: simply effects of optimized drug treatment?. European Heart Journal, 2005, 26, 1685-1685.	1.0	3

#	Article	IF	Citations
397	Sports or statins for atheroprotection? New insight from Kruppel-like factor 2. Cardiovascular Research, 2006, 72, 193-195.	1.8	3
398	MicroRNAs in cardiac hypertrophy and failure. Drug Discovery Today Disease Mechanisms, 2008, 5, e279-e283.	0.8	3
399	Exosomal MicroRNAs Released by Pediatric Cardiac Progenitor Cells. Circulation Research, 2017, 120, 607-609.	2.0	3
400	Reconstruction of the miR-506-Quaking axis in Idiopathic Pulmonary Fibrosis using integrative multi-source bioinformatics. Scientific Reports, 2021, 11, 12456.	1.6	3
401	Detection and Transport Mechanisms of Circulating microRNAs in Neurological, Cardiac and Kidney Diseases. Current Medicinal Chemistry, 2013, 20, 3623-3628.	1.2	3
402	Circulating microRNAs in Symptomatic and Asymptomatic Carotid Stenosis. Frontiers in Neurology, 2021, 12, 755827.	1.1	3
403	Comprehensive Expression Analysis of Cardiac Fibroblast Growth Factor 23 in Health and Pressure-induced Cardiac Hypertrophy. Frontiers in Cell and Developmental Biology, 2021, 9, 791479.	1.8	3
404	Tilarginine in Patients With Acute Myocardial Infarction and Cardiogenic Shock. JAMA - Journal of the American Medical Association, 2007, 298, 969.	3.8	2
405	Response to Letter Regarding Article, â€œCirculating Endothelial Progenitor Cells in Patients With Eisenmenger Syndrome and Idiopathic Pulmonary Arterial Hypertensionâ€• Circulation, 2009, 119, .	1.6	2
406	MicroRNAs Looping Around Angiogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011, 31, 2367-2368.	1.1	2
407	MicroRNAs deciding cardiac stem cell fate. Journal of Molecular and Cellular Cardiology, 2012, 53, 747-748.	0.9	2
408	MicroRNA-223 Made Its Way Into Vascular Research. Circulation Research, 2013, 113, 1270-1271.	2.0	2
409	Towards novel theranostic approaches in cardiac transplantation medicine. European Heart Journal, 2014, 35, 3152-3154.	1.0	2
410	Letter by Pinet et al Regarding Article, â€œComparative Analysis of Circulating Noncoding RNAs Versus Protein Biomarkers in the Detection of Myocardial Injuryâ€• Circulation Research, 2019, 125, e20-e21.	2.0	2
411	Pharmacokinetic Studies of Antisense Oligonucleotides Using MALDI-TOF Mass Spectrometry. Frontiers in Pharmacology, 2020, 11, 220.	1.6	2
412	MicroRNAs: Novel Therapeutic Targets for Diabetic Wound Healing. Contemporary Diabetes, 2018, , 237-246.	0.0	2
413	ADMA, endothelial progenitor cells, and cardiovascular risk. Circulation Research, 2005, 97, e84.	2.0	2
414	Orchestration of vascular smooth muscle cell plasticity using epigenetic therapy. European Heart Journal, 2022, 43, 4577-4578.	1.0	2

#	Article	IF	Citations
415	Letter by Thum et al Regarding Article, â€œOxidant Stress Impairs In Vivo Reendothelialization Capacity of Endothelial Progenitor Cells From Patients With Type 2 Diabetes Mellitus: Restoration by the Peroxisome Proliferator- Activated Receptor-Î³ Agonist Rosiglitazoneâ€• Circulation, 2008, 117, e185; author reply e186.	1.6	1
416	Antiageing concepts and cardiovascular disease. European Heart Journal, 2015, 36, 3435-3436.	1.0	1
417	MiR-142-3p is a paracrine mediator between T cells and endothelium during allograft rejection. Cardiovascular Research, 2017, 113, 431-433.	1.8	1
418	Refractory angina revisited: stem cells for a growing unmet clinical need?. European Heart Journal, 2018, 39, 2217-2219.	1.0	1
419	FO083CHRONIC FGF23 OVERLOAD FAILS TO INDUCE CARDIAC DYSFUNCTIONS. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	1
420	A new diastolic dysfunction disease-modelling platform. European Heart Journal, 2019, 40, 3696-3698.	1.0	1
421	Using â€œoldâ€•medications to fight new COVID-19: Re-purposing with a purpose. Journal of Molecular and Cellular Cardiology, 2020, 146, 41-42.	0.9	1
422	Dichotomy between the transcriptomic landscape of naturally versus accelerated aged murine hearts. Scientific Reports, 2020, 10, 8136.	1.6	1
423	Abstract 114: Safety And Efficacy Of CDR132L, A Novel Antisense Therapeutic Which Targets MicroRNA-132 In Heart Failure Patients. Circulation Research, 2021, 129, .	2.0	1
424	Growth hormone treatment improves markers of systemic nitric oxide bioavailability via the insulin-like growth factor-1 Importance for endothelial progenitor cells. Journal of Stem Cells and Regenerative Medicine, 2007, 2, 115-6.	2.2	1
425	MicroRNA-449a Inhibits Triple Negative Breast Cancer by Disturbing DNA Repair and Chromatid Separation. International Journal of Molecular Sciences, 2022, 23, 5131.	1.8	1
426	Editorial [Hot topic: MicroRNAs: from Basic Regulation Towards Therapeutic Approaches - Passion, Caution and Patience Required (Guest Editor: Dr. Thomas Thum)]. Current Drug Targets, 2010, 11, 898-899.	1.0	0
427	The BALANCE Study. Journal of the American College of Cardiology, 2010, 55, 263-264.	1.2	0
428	MicroRNA and disease models: focus on cardiac fibrosis. Drug Discovery Today: Disease Models, 2013, 10, e115-e119.	1.2	0
429	DIABETES EXPERIMENTAL. Nephrology Dialysis Transplantation, 2014, 29, iii168-iii177.	0.4	0
430	Summary of basic science activities at the European Society of Cardiology Congress in Barcelona 2014. ESC Heart Failure, 2014, 1, 166-169.	1.4	0
431	TISSUE INJURY AND REPAIR. Nephrology Dialysis Transplantation, 2014, 29, iii23-iii24.	0.4	0
432	178â€…Circulating Micrornas for Predicting and Monitoring Response to Mechanical Circulatory Support from a left Ventricular Assist Device. Heart, 2014, 100, A100.2-A101.	1.2	0

#	Article	IF	Citations
433	Reply. Hepatology, 2015, 61, 1440-1441.	3.6	0
434	MicroRNA-Mediated Regulation of Cardiovascular Differentiation and Therapeutic Implications. , 2015, , 1075-1091.		0
435	Novel models and mechanisms of heart failure with preserved ejection fraction. European Journal of Heart Failure, 2016, 18, 998-999.	2.9	0
436	199â€…Takotsubo syndrome associated mir-16 and mir-26a reduce contractility of cardiomyocytes in vitro by an inhibitory g-?protein dependent mechanism. Heart, 2017, 103, A135.1-A135.	1.2	0
437	34â€…Proteomic and micro rna biomarker discovery to identify novel markers of left ventricular diastolic dysfunction in patients with diabetes. , 2017, , .		0
438	A long way for microRNAs to become meaningful prognostic biomarkers. European Journal of Heart Failure, 2018, 20, 76-77.	2.9	0
439	Vascular Smooth Muscle Cell Remodeling. Circulation Research, 2018, 123, 1261-1263.	2.0	0
440	FP280FUNCTIONAL INVESTIGATION OF MIR-17-5P INHIBITION IN KIDNEY ISCHEMIA-REPERFUSION INJURY IN MICE. Nephrology Dialysis Transplantation, 2019, 34, .	0.4	0
441	The Janus Face of miR-148a in Cardiac Remodeling and Heart Failure. Molecular Therapy, 2019, 27, 489-490.	3.7	0
442	The Institute of Molecular and Translational Therapeutic Strategies, Hannover Medical School, Germany. European Heart Journal, 2020, 41, 1459-1461.	1.0	0
443	The ESC Working Group on Myocardial Function. European Heart Journal, 2020, 41, 2346-2348.	1.0	0
444	FC 018HIGH DIETARY PHOSPHATE INTAKE AND INTRA-CARDIAC SYNTHESIS OF FIBROBLAST GROWTH FACTOR 23 SYNERGISTICALLY WORSEN CARDIAC FUNCTION. Nephrology Dialysis Transplantation, 2021, 36, .	0.4	0
445	Diagnostic value of circulating microRNAs compared to high-sensitivity troponin T for the detection of non-ST-segment elevation myocardial infarction. European Heart Journal, 2021, 42, .	1.0	0
446	Absence of microRNAâ€155 protects against pressure overloadâ€induced cardiac inflammation and failure. FASEB Journal, 2012, 26, 137.5.	0.2	0
447	COVID-19: Winzige MolekÃ¼le belegen Herz- und GefÃÃŸbeteiligung. , 0, , .		0
448	Aldosterone mediated dysfunction of human endothelial progenitor cells - Mechanisms and therapeutic opportunities. Journal of Stem Cells and Regenerative Medicine, 2007, 2, 39-40.	2.2	0
449	Malfunction of endothelial progenitor cells and endothelial function in patients with Fabry disease. Journal of Stem Cells and Regenerative Medicine, 2007, 2, 161-2.	2.2	0
450	Recent patents on stem cell transplantation in cardiovascular medicine. Journal of Stem Cells and Regenerative Medicine, 2007, 2, 207-8.	2.2	0

#	Article	IF	Citations
451	Deciphering Pro-angiogenic Transcription Factor Profiles in Hypoxic Human Endothelial Cells by Combined Bioinformatics and in vitro Modeling. Frontiers in Cardiovascular Medicine, 0, 9, .	1.1	0